Top Markets
Coin of the day
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
Rang in Aktien #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aktienkurs
$70.50
Zuletzt synchronisiert: 2025-11-14
Marktkapitalisierung
$7.33B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
116.32%
Land
US
Handel Metsera, Inc. (MTSR)

Kategorie

Dividendenrendite-Verlauf für Metsera, Inc. (MTSR)
Dividendenrendite (TTM) von Metsera, Inc. (Aktienkürzel: MTSR) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Metsera, Inc. (MTSR) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH